The Global Skin Cancer Diagnostics & Therapeutics Market (2018-2023): The High Cost Associated with Therapy is Hindering Growth - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 26, 2018--The “Global Skin Cancer Diagnostics and Therapeutics Market Share - Segmented by Cancer Type, Process (Diagnosis and Treatment), and Geography - Growth, Trends, and Forecast (2018 - 2023)” report has been added to ResearchAndMarkets.com’s offering.The skin cancer diagnostics and therapeutics market is expected to register a CAGR of 9.2%, over the forecast period.
Apart from the increasing incidence of skin cancer, factors such as favorable government initiatives, the development of novel immunotherapies, and the extension of current therapies are driving the global market for skin cancer diagnostics and therapeutics.
Despite high disease burden and major technological advantages in the field of cancer treatment, the cost of therapies remain high, and the cost of therapies for the management of skin cancer is significantly higher in comparison to other forms of cancer. High cost associated with diagnosis and management remains the major barrier for market growth, especially in developing countries.
Other factors that could potentially impede the growth of the market include a stringent regulatory environment and the lack of awareness about the disease and its progression.
Key Developments in the MarketFDA approved BAVENCIO (AVELUMAB), which is an injection for the treatment of patients with locally advanced or metastatic urothelial carcinoma. The formulation was jointly developed by Pfizer Inc. and Merck KGaA. Companies ProfiledAbbott Inc.Agilent Technologies Inc.AstraZeneca PLCBristol-Myers Squibb Co.Eli Lilly and Co.GlaxoSmithKline PLCMerck & Co. Inc.Novartis AGPfizer Inc.Qiagen N.V.F. Hoffmann-La Roche AGSanofi S.A.
Key Topics Covered
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
6. Market Dynamics
7. Market Segmentation
8. Skin Cancer Diagnostics & Therapeutics Market Key Players and Competitive Landscape9. Future of the Skin Cancer Diagnostics & Therapeutics Market
For more information about this report visit https://www.researchandmarkets.com/research/rl6d9c/the_global_skin?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180926005391/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Diagnostics,Skin Cancer Drugs,Dermatological Drugs
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/26/2018 06:30 AM/DISC: 09/26/2018 06:30 AM